Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | FNTB | P49356 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | BRS3 | P32247 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630123 | 0.78 | SLC6A3 (0.43) | KDM4EALDH1A1LTB4R2FNTAFNTB | |
| SCHEMBL628630 | 0.76 | LOXL2 (0.50) | KDM4EALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6624770 | 0.76 | SLC6A3 (0.46) | KDM4EALDH1A1LTB4R2SLC6A2SLC6A4 | |
| SCHEMBL629251 | 0.76 | KDM4E (0.40) | KDM4EALDH1A1FNTAFNTBSLC6A2 | |
| SCHEMBL6625716 | 0.75 | SLC6A3 (0.43) | HTR7KDM4EALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL6774395 | 0.75 | SLC6A3 (0.44) | HTR7KDM4EALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL6772428 | 0.75 | BRD9 (0.43) | HTR7KDM4EALDH1A1 | |
| SCHEMBL628506 | 0.75 | PTPN1 (0.39) | KDM4EALDH1A1FNTAFNTBSLC6A2 | |
| SCHEMBL630057 | 0.75 | MEN1 (0.46) | KDM4EALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5548483 | 0.75 | LOXL2 (0.52) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | HTR7 2774/4885TACR1 3793/4885KDM4E 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.